NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Abiraterone for the treatment of metastatic castration-resistant prostate cancer not previously treated with chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes.

Issue 1

The scope remit and population refer to men with prostate cancer. An issue was raised during the scoping workshop regarding people who have undergone gender reassignment. People who have undergone a male-to-female gender reassignment will still have a prostate and can therefore develop cancer of the prostate. The issue raised was that those people may be uncomfortable accessing a male urology clinic. Additionally, using the term 'men' in the remit and population section would not be appropriate for this population.

Issue 2

It was noted in consultation that prostate cancer is more common in African-Caribbean mean and men over 60 years of age, and that men from lower socioeconomic backgrounds are less likely to survive prostate cancer than those from more affluent backgrounds

2. What is the preliminary view as to what extent these potential equality

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of abiraterone for the treatment of metastatic castration-resistant prostate cancer not previously treated with chemotherapy Issue date: December 2012

issues need addressing by the Committee?

Issue1

Consultees recommended that the appraisal committee be aware of any potential restrictions to access to urology clinics for people who have undergone gender reassignment.

Issue 2

Differences in prevalence alone cannot be addressed within a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Issue 1

Yes. Consultees concluded that the wording of the remit and scope population should be changed to accommodate people who have undergone gender reassignment. Reference to 'men' was removed from remit and population and replaced with 'people'.

Issue 2

No changes to the draft scope were required

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Elisabeth George...

Date: 29 11 12

Technology Appraisals: Scoping Equality impact assessment for the proposed Single Technology Appraisal of abiraterone for the treatment of metastatic castration-resistant prostate cancer not previously treated with chemotherapy Issue date: December 2012